Travere Therapeutics is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results